<DOC>
	<DOCNO>NCT00617604</DOCNO>
	<brief_summary>The purpose study determine whether alefacept effective well tolerate use combination tacrolimus , mycophenolate mofetil steroid versus combination therapy placebo , tacrolimus steroid prevention kidney transplant rejection .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety Alefacept Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Subject end stage kidney disease suitable candidate primary kidney transplantation retransplantation Male female subject least 18 year age young 65 year Subject receive kidney transplant nonhuman leucocyte antigen ( HLA ) identical living donor decease HLA identical/nonHLA identical donor 5 59 year age compatible ABO blood type ( Blood group system A , B , AB 0 ) Subject panel reactivity antibody grade &gt; 20 % previous 6 month and/or previous graft survival shorter 1 year due immunological reason Subject receive kidney transplant nonheart beat donor Subject receive kidney transplant 50 59 year old donor two follow three factor : history hypertension , cerebrovascular accident cause death , final preprocurement serum creatinine &gt; 1.5 mg/dL ( united network organ share [ UNOS ] expand criterion donor ) Cold ischemia time donor kidney â‰¥ 30 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>kidney transplant</keyword>
	<keyword>alefacept</keyword>
</DOC>